702 Results

People

  1. Motzer
    Motzer
  2. Livingston
    Livingston
  3. Norton
    Norton
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Krown
    Krown
  7. Sepkowitz
    Sepkowitz
  8. O'Reilly
    O'Reilly
  9. Panageas
    Panageas
  10. Horwitz
    Horwitz

Groups

  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)
  7. Epidemiology and Biostatistics (73)
  8. GSK Faculty (73)
  9. Division of Subspecialty Medicine (65)
  10. Gastrointestinal Oncology Service (64)
  1. "fever"
Formats
  1. Journal Article (657)
  2. Review (23)
  3. Conference Paper (6)
  4. Research Letter (6)
  5. Guidelines (5)
  6. Editorial (4)
  7. Correspondence (1)
Groups
  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)

More Groups

People
  1. Robert Motzer (24)
  2. Larry Norton (20)
  3. Philip Livingston (19)
  4. Carol Aghajanian (17)
  5. Clifford Hudis (17)
  6. Kent Sepkowitz (17)

More People

Years
  1. 2025 (21)
  2. 2024 (42)
  3. 2023 (40)
  4. 2022 (22)
  5. 2021 (25)
  6. 2020 (44)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Clinical Cancer Research (33)
  3. Blood (22)
  4. Lancet Oncology (22)
  5. Cancer (21)
  6. New England Journal of Medicine (18)

More Publications

Publishers
  1. Elsevier Inc. (107)
  2. American Society of Clinical Oncology (70)
  3. Elsevier Science, Inc. (55)
  4. Springer (53)
  5. Nature Publishing Group (40)
  6. Wiley Blackwell (38)

More Publishers

Results (702)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Journal Article

    Nooka, A. K.; Cohen, A. D.; Lee, H. C.; Badros, A.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study
    Journal Article

    McGuirk, J. P.; Metheny, L.; Pineiro, L.; Litzow, M.; Rowley, S. D.; Avni, B.; Tamari, R.; Lazarus, H. M.; Rowe, J. M.; Sheleg, M.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Combined hepatic arterial infusion pump and systemic chemotherapy in the modern era for chemotherapy-naive patients with unresectable colorectal liver metastases
    Journal Article

    Verheij, F. S.; Kuhlmann, K. F. D.; Silliman, D. R.; Soares, K. C.; Kingham, T. P.; Balachandran, V. P.; Drebin, J. A.; Wei, A. C.; Jarnagin, W. R.; Cercek, A.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Sepsis and adrenal insufficiency
    Review

    Fowler, C.; Raoof, N.; Pastores, S. M.
    Journal of Intensive Care Medicine (2023)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial
    Journal Article

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Chari, A.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
    Journal Article

    Han, S. N.; Oza, A.; Colombo, N.; Oaknin, A.; Raspagliesi, F.; Wenham, R. M.; Braicu, E. I.; Jewell, A.; Makker, V.; Krell, J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma
    Journal Article

    Klempner, S. J.; Lee, K. W.; Shitara, K.; Metges, J. P.; Lonardi, S.; Ilson, D. H.; Fazio, N.; Kim, T. Y.; Bai, L. Y.; Moran, D.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
    Journal Article

    Pignata, S.; Bookman, M.; Sehouli, J.; Miller, A.; Penson, R. T.; Taskiran, C.; Anderson, C.; Hietanen, S.; Myers, T.; Madry, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma
    Journal Article

    Lin, A. L.; Tabar, V.; Young, R. J.; Geer, E. B.
    Pituitary (2023)

    Fulltext@MSK | Save